Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing STS101 nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, announced that John Kollins, its President and Chief Executive Officer, is scheduled to present at the Cantor Virtual Global Healthcare Conference and invites investors to participate via webcast and in one-on-one meetings.
September 28, 2021
· 2 min read